Table 4 Onset of 50% maintenance of response in patients with episodic and chronic migraine: percentage of patients reach 50% response at each month and all the subsequent months
Episodic migraine | Chronic migraine | |||||
|---|---|---|---|---|---|---|
Galcanezumab 120 mg (N = 436) | Galcanezumab 240 mg (N = 428) | Placebo (N = 875) | Galcanezumab 120 mg (N = 273) | Galcanezumab 240 mg (N = 274) | Placebo (N = 538) | |
Month 1 | 19.0% | 20.8% | 8.0% | 14.8% | 12.7% | 5.6% |
Month 2 | 6.2% | 7.7% | 5.0% | 4.5% | 6.6% | 6.2% |
Month 3 | 6.0% | 4.3% | 3.2% | 10.9% | 13.1% | 9.0% |
Month 4 | 7.8% | 5.1% | 4.2% | N/A | N/A | N/A |
Month 5 | 6.9% | 8.5% | 5.8% | N/A | N/A | N/A |
Month 6 | 10.6% | 7.9% | 10.9% | N/A | N/A | N/A |